The collaborative project aims to develop a “novel, revolutionary” approach to treat COVID-19 by using the non-psychoactive compound CBD.
Specifically it hopes to treat the virus using CBD-loaded exomes – small particles created when stem cells are multiplied.
Exosomes can act as “homing missiles”, targeting specific damaged organs and have an important role in cell-to-cell communication.
Revolutionary exosome-based technology has the potential to target both central nervous system (CNS) problems and the COVID-19 virus.
CBD-loaded exosomes could provide a “highly synergistic” effect of anti-inflammatory properties and help in the recovery of infected lung cells.
A new product based on this technology, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
The study is backed by Israeli firm InnoCan Pharma Ltd, which has entered a sponsored research agreement with Ramot, the technology transfer arm of Tel Aviv University.
They hope to develop a cell therapy product based on Professor Daniel Offen’s ongoing work in the field, with InnoCan contributing around US$450,000 to the first stage of the study.
The research results could lead to the development of and manufacture of a product to treat COVID-19 and, potentially, other types of lung inflammations and additional respiratory related illnesses.